Role of subcellular remodeling in cardiac dysfunction due to congestive heart failure

Medical Principles and Practice

Volumn 16, Issue 2, 2007, Pages 81-89

  Babick, Andrea P ^a   Dhalla, Naranjan S ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Cardiac gene expression; Cardiac hypertrophy; Myocardial infarction; Pressure overload; Volume overload

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PHOSPHOLAMBAN; SODIUM CALCIUM EXCHANGE PROTEIN;

CALCIUM TRANSPORT; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; ENZYME ACTIVITY; ENZYME MODIFICATION; GENE EXPRESSION; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PERFORMANCE; HEART SIZE; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE HYPERTROPHY; HUMAN; MEMBRANE DEPOLARIZATION; MUSCLE FIBRIL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPLASMIC RETICULUM; SODIUM CALCIUM EXCHANGE; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; CARDIOMEGALY; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOFIBRILS; RENIN-ANGIOTENSIN SYSTEM; SARCOLEMMA; SARCOPLASMIC RETICULUM;

EID: 33847015132     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098358     Document Type: Review

References (105)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
2. Dhalla NS, Afzal N, Beamish RE, Naimark B, Takeda N, Nagano M: Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol 1993;9:873-887.
3. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-3072.
4. Zeltsman D, Acker MA: Surgical management of heart failure: an overview. Annu Rev Med 2002;53:383-391.
5. Deten A, Volz H, Briest W, Zimmer H: Differential cytokine expression in myocytes and non-myocytes after myocardial infarction in rats. Mol Cell Biochem 2003;242:47-55.
6. Declayre C, Swynghedauw B: Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 2002;34:1577-1584.
7. Rouleau JL: The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol 1996;12(suppl F):3F-8F.
8. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869-877.
9. Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-262.
10. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-582.
11. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-1172.
12. Bayer AL, Heidkamp MC, Patel N, Porter M, Engman S, Samarel AM: Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy. Mol Cell Biochem 2003;242:145-152.
13. 2+ transport and mechanics in compensated pressure-overload hypertrophy and congestive heart failure. Circ Res 1995;77:759-764.
14. Arai M, Suzuki T, Nagai R: Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but downregulated in severe cardiac hypertrophy induced by pressure overload. J Mol Cell Cardiol 1996;28:1583-1590.
15. Hisamatsu Y, Ohkusa T, Kihara Y, Inolo M, Ueyama T, Yano M, Sasayama S, Tatsuzuki M: Early changes in the functions of cardiac sarcoplasmic reticulum in volume-overloaded cardiac hypertrophy in rats. J Mol Cell Cardiol 1997;29:1097-1109.
16. Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS: Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 2003;94:752-763.
17. Sentex E, Wang X, Liu X, Lukas A, Dhalla NS: Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload. Can J Physiol Pharmacol 2006:84:227-238.
18. Hutchins GM, Bulkley EH: Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978;41:1127-1132.
19. Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen matrix. J Am Coll Cardiol 1989;13:1637-1652.
20. Sabbah HN, Goldstein S: Ventricular remodeling: consequence and therapy. Eur Heart J 1993;14:24-29.
21. Weber KT, Brill CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
22. 1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997;35:223-232.
23. Briest W, Holzl A, Rabler B, Deten A, Baba HA, Zimmer H: Significance of matrix metalloproteinases in norepinephrine-induced remodeling of rat hearts. Cardiovasc Res 2003;57:379-387.
24. Weber KT, Clark WA, Janicki JS, Shroff SG: Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium. J Cardiovasc Pharmacol 1987;10(suppl):S37-S49.
25. Zannad F, Radauceanu A: Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 2005;10:71-78.
26. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA: Effects of angiotensin converting enzyme inhibitors and angiotensin II type1-receptor antagonists in rats with heart failure. J Clin Invest 1997;26:101-111.
27. Weber KT: Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens 2004;22:47-50.
28. Dhalla NS, Wang X, Beamish RE: Intracellular calcium handling in normal and failing hearts. Exp Clin Cardiol 1996;1:7-20.
29. Davies CH, Harding SE, Poole-Wilson PA: Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 1996;17:189-198.
30. Palermo J, Gulick J, Colbert M, Fewell J, Robbins J: Transgenic remodeling of the contractile apparatus in the mammalian heart. Circ Res 1996;78:504-509.
31. Dhalla NS, Shao Q, Panagia V: Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev 1998;2:261-272.
32. Morgan JP, Erny RE, Allen PD, Grossman W, Gwathmey JK: Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990;81(suppl):III21-III32.
33. Dhalla NS, Dixon IMC, Beamish RE: Biochemical basis of heart function and contractile failure. J Appl Cardiol 1991;6:7-30.
34. Schwinger RH, Bundgaard H, Muller-Ehmsen J, Kjeldsen K: The Na, K-ATPase in the failing human heart. Cardiovasc Res 2003;57:913-920.
35. Horisberger JD, Lemas V, Kraehenbuhl JP, Rossier BC: Structure-function relationship of Na,K-ATPase. Annu Rev Physiol 1991;53:565-584.
36. Charlemagne D, Orlowski J, Oliviero P, Rannou F, Saint Beuve C, Swynghedauw B, Lane LK: Alteration of Na, K-ATPase subunit mRNA and protein levels in hypertrophied rat heart. J Biol Chem 1994;269:1541-1547.
37. +-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol Cell Physiol 1992;262:C664-C671.
38. +-pump capacity in congestive heart failure following myocardial infarction in rats. J Mol Cell Cardiol 1998;30:1311-1328.
39. +-ATPase subunit isoforms at mRNA and protein levels in rat myocardium. J Mol Cell Cardiol 1994;26:591-600.
40. + ATPase subunits in the UM-X7.1 cardiomyopathic hamster. Life Sci 2000;67:1175-1183.
41. 2+ exchanger expression in heart failure by blockade of renin-angiotensin system. Am J Physiol Heart Circ Physiol 2005;288:H2637-2646.
42. Ren B, Shao Q, Ganguly PK, Tappia PS, Takeda N, Dhalla NS: Influence of long-term treatment of imidapril on mortality, cardiac function, and gene expression in congestive heart failure due to myocardial infarction. Can J Physiol Pharmacol 2004;82:1118-1127.
43. 2+ exchanger. Science 1990;250:562-565.
44. 2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-453.
45. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999;99:641-648.
46. Dixon IMC, Hata T, Dhalla NS: Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am J Physiol Heart Circ Physiol 1992;262:H1387-H1394.
47. 2+ exchanger in end-stage failing human myocardium. Eur Heart J 2002;23:1118-1124.
48. 2+ exchange activity in patients with end-stage heart failure. Cardiovasc Res 1996;31:48-54.
49. 2+-dependent adenosine triphosphatase from rat cardiac sarcoplasmic reticulum. J Clin Invest 1989;83:1102-1108.
50. Muliere LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR: Altered myocardial forcefrequency relation in human heart failure. Circulation 1992;85:1743-1750.
51. 2+ -ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990;85:305-309.
52. Brillantes AM, Allen P, Takahashi T, Izumo S, Marks AR: Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with endstage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res 1992;71:18-26.
53. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-469.
54. 2+ ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92:3320-3228.
55. Meyer M, Schilinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just J, Hasenfuss G: Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-784.
56. Toffolo RL, Ianuzzo CD: Myofibrillar adaptations during cardiac hypertrophy. Mol Cell Biochem 1994;131:141-149.
57. Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS: Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol 2002;34:847-857.
58. Movsesian MA, Schwinger RHG: Calcium sequestration by the sarcoplasmic reticulum in heart failure. Cardiovasc Res 1998;37:352-359.
59. 2+ ATPase in contractile dysfunction of myocytes in tachycardia-induced heart failure. Am J Physiol Heart Circ Physiol 1998;275:H31-H40.
60. Hisamatsu Y, Ohkusa T, Kihara Y, Inoko M, Ueyama T, Yano M, Sasayama S, Matsuzaki M: Early changes in the function of cardiac sarcoplasmic reticulum in volume-overloaded cardiac hypertrophy in rats. J Mol Cell Cardiol 1997;29:1097-1109.
61. 2+ transport and gene expression in congestive heart failure are modified by imidapril treatment. Am J Physiol Heart Circ Physiol 2005;288:H1674-H1682.
62. 2+ ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997;15:1001-1009.
63. 2+ pump ATPase. J Biol Chem 1992;267:1674-1679.
64. Luo W, Gurpp IL, Harrer J, Ponniah S, Grupp G, Dufy JJ, Doetschman T, Kranias EG: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 1994;75:401-409.
65. Holmberg SR, Williams AJ: The calcium-release channel from cardiac sarcoplasmic reticulum: function in the failing and acutely ischemic heart. Basic Res Cardiol 1992;87(suppl 1):255-268.
66. Cory CR, McCutcheon LJ, O'Grady M, Pang AW, Geiger JD, O'Brien PJ: Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. Am J Physiol Heart Circ Physiol 1993;33:H926-H937.
67. Morano I, Hadicke K, Haase H, Bohm M, Erdmann E, Schaub MC: Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol 1997;29:1177-1187.
68. Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD: Troponin T isoform expression in the normal and failing human left ventricle: a correlation with myofibrillar ATPase activity. Basic Res Cardiol 1992;87(suppl 1):117-127.
69. Solaro RJ, Powers FM, Gao L, Gwathmey JK: Control of myofilament activation in heart failure. Circulation 1993;87(suppl VII):38-43.
70. Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban SW, Allen PD: Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 1988;63:380-385.
71. Alousi AA, Grant AM, Etzler LR, Cofer BR, Van der Bel-Kahn J, Melvin D: Reduced cardiac myofibrillar Mg-ATPase activity without changes in myosin isozymes in patients with end-stage heart failure. Mol Cell Biochem 1990;96:79-88.
72. Buttrick P, Malhotra A, Factor S, Greene D, Scheuer J: Effect of chronic dobutamine administration on hearts of normal and hypertensive rats. Circ Res 1988;63:173-181.
73. Izumo S, Lompre A, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, Mahdavi V: Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest 1987;79:970-977.
74. Eble DM, Walker JD, Mukherjee R, Samarel AM, Spinale FG: Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol Heart Circ Physiol 1997;272:H969-H978.
75. Imamura T, McDermott PJ, Kent RL, Nagatsu M, Cooper G, Carabello BA: Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload. Circ Res 1994;75:418-425.
76. Wang J, Guo X, Dhalla NS: Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim Biophys Acta 2004;1690:177-184.
77. Guo X, Saini HK, Wang J, Gupta SK, Goyal RK, Dhalla NS: Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. Expert Rev Cardiovasc Ther 2005;3:717-732.
78. Feldman AM: Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation 1993;87(suppl IV):IV27-IV34.
79. Bohm M, Diett F, Feiler G, Kemkes B, Erdmann E: -Adrenoceptors and α-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 1988;12:357-364.
80. 2-adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303.
81. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302.
82. Hadcock JR, Malbon CC: Down-regulation of β-adrenergic receptors: agonist-induced reduction in mRNA levels. Proc Natl Acad Sci USA 1988;85:5021-5025.
83. oα mRNA level and pertussis toxinsensitive guanine nucleotide-binding proteins in rat heart. Mol Pharmacol 1992;42:773-783.
84. 2+ ATPase gene expression in congestive heart failure: effect of chronic norepinephrine infusion. J Mol Cell Cardiol 1998;30:175-185.
85. Ju H, Scammell-La Fleur T, Dixon IMC: Altered mRNA abundance of calcium transport genes in cardiac myocytes induced by angiotensin II. J Mol Cell Cardiol 1996;28:1119-1128.
86. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C: Angiotensin II induces nuclear factor-κB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 2000;32:1767-1778.
87. Jugdutt BI, Schwarz-Michorowski BL, Khan MI: Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. J Am Coll Cardiol 1992;19:713-721.
88. McDonald KM, Chu C, Francis GS, Carlyle W, Judd DL, Hauer K, Hartman M, Cohn JN: Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model myocardial infarction. J Mol Cell Cardiol 1997;29:3203-3210.
89. Dixon IMC, Ju H, Jassal DS, Peterson DJ: Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction. Mol Cell Biochem 1996;165:31-45.
90. Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2001-2018.
91. Fedak PWM, Verma S, Weisel RD, Li RK: Cardiac remodeling and failure from molecules to man (part 1). Cardiovasc Physiol 2005;12:1-11.
92. Baig MK, Mahon N, McKenna WJ, Caforio ALP, Bonow RD, Francis GS, Gheorghiade M: The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-S230.
93. Dhalla NS, Dent MR, Tappia PS, Sethi R, Barta J, Goyal RK: Subcellular remodeling as a viable target for the treatment of congestive heart failure. J Cardiovasc Pharmacol Ther 2006;11:31-45.
94. Boheler KR, Volkova M, Morrell C, Garg R, Zhu Y, Margulies K, Seymour AM, Lakatta EG: Sex- and age-dependent human transcriptome variability: implications for chronic heart failure. Proc Natl Acad Sci USA 2003;100:2754-2759.
95. Tabibiazar R, Wagner RA, Liao A, Quertermous T: Transcriptional profiling of the heart reveals chamber-specific gene expression patterns. Circ Res 2003;93:1193-1201.
96. Laframboise WR, Bombach KL, Dhir RJ, Muka N, Cullen RF, Pogozelski AR, Turk D, Geouge JD, Guthrie RD, Magovern JR: Molecular dynamics of the compensatory response to myocardial infarct. J Mol Cell Cardiol 2005;38:547-550.
97. Sharma UC, Pokharel S, Evelo CR, Maessen JG: A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cell Cardiol 2005;38:425-432.
98. Liew CC: Expressed genome molecular signatures of heart failure. Clin Chem Lab Med 2005;43:462-469.
99. Steenman M, Lamirault G, Le Meur N, Leger JJ: Gene expression profiling in human cardiovascular disease. Clin Chem Lab Med 2005;43:696-701.
100. Houser SR, Piacentino V 3rd, Weisser J: Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000;32:1595-1607.
101. Bing OHL, Conrad CH, Boluyt MO, Robinson KG, Brooks WW: Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. Heart Fail Rev 2002;7:71-88.
102. Pacher P, Mabley JG, Liaudet L, Evgenov OV, Marton A, Hasko G, Kollai M, Szabo C: Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol 2004;287:H2132-H2137.
103. Mengi SR, Dhalla NS: Carnitine palmitoyltransferase-I, a new target for the treatment of heart failure: perspectives on a shift in myocardial metabolism as a therapeutic intervention. Am J Cardiovasc Drugs 2004;4:201-209.
104. + exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol 2000;278:H300-H304.
105. Sethi R, Shao Q, Ren B, Saini HK, Takeda N, Dhalla NS: Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system. Mol Cell Biochem 2004;263:11-20.